Sign in

You're signed outSign in or to get full access.

Evelyn S. Dilsaver

Director at SOMNIGROUP INTERNATIONAL
Board

About Evelyn S. Dilsaver

Evelyn S. Dilsaver, 69, has served on Somnigroup International Inc.’s Board since December 2009; she is a certified public accountant with a B.S. in accounting from California State University–Hayward and previously served as President & CEO of Charles Schwab Investment Management and as CFO of U.S. Trust Company . The Board has determined she is independent under NYSE rules; all Audit Committee members (she chairs) are deemed “audit committee financial experts,” reflecting her accounting and financial management expertise .

Past Roles

OrganizationRoleTenureCommittees/Impact
Charles Schwab Investment ManagementPresident & CEOJul 2004 – Sep 2007Led asset management products/services; senior executive leadership
The Charles Schwab CorporationExecutive VP/Senior VP (Asset Mgmt Products & Services)Various roles since Dec 1991Senior management of investment products
U.S. Trust CompanyChief Financial OfficerNot disclosedCorporate finance leadership

External Roles

OrganizationRoleStatusCommittees
HealthEquity, Inc. (HQY)DirectorCurrentChair, Nominating, Governance & Sustainability; Member, Talent Compensation & Culture
PACS Group, Inc. (PACS)DirectorCurrentChair, Nominating & Corporate Governance; Member, Compensation; Member, Audit
QuidelOrtho Corporation (QDEL)DirectorCurrentNot disclosed
Bailard Private Real Estate FundDirectorCurrentNot disclosed
Protiviti Inc.Advisory Board MemberCurrentNot disclosed
AeropostaleDirectorPriorNot disclosed
Blue Shield of CaliforniaDirectorRecent priorNot disclosed

Board Governance

  • Committee assignments: Audit Committee Chair; Nominating & Corporate Governance Committee member .
  • Independence: Determined independent under NYSE rules (board majority independent); Audit Committee members designated as “audit committee financial experts” .
  • Attendance: Board held seven meetings in 2024; each director attended more than 75% of combined Board and committee meetings; all directors attended the May 9, 2024 annual meeting .
  • Executive sessions: Independent directors met several times without management, led by the Lead Director .
  • Committee activity: Audit Committee met 6 times; Nominating & Corporate Governance Committee met 4 times in 2024 .

Fixed Compensation

Component (2024 Board Year)AmountDetail
Annual Cash Retainer$110,000Paid in equal quarterly installments
Audit Committee Chair Retainer$20,000Chair premium
Total Cash Fees (2024 paid)$130,000Fees earned/paid in 2024 reflect 2023 H2 + 2024 YTD
Annual Equity Award Target$150,000Granted as RSUs
RSUs Granted (#)2,778Grant date fair value $149,984

Notes: No committee member retainer; no meeting fees; reimbursement of reasonable expenses; Lead Director retainer applies to Mr. Neu, not Ms. Dilsaver .

Performance Compensation

  • Non-employee directors receive time-based RSUs; there are no performance-based equity awards, AIP, or PSU metrics for directors. Annual equity awards are RSUs targeted at $150,000; 2,778 RSUs were granted to Ms. Dilsaver with grant date fair value $149,984 .

Other Directorships & Interlocks

CompanySector Overlap with SGIInterlock RiskNotes
HealthEquity (HQY)Healthcare/Financial servicesLow (no disclosed customer/supplier ties to SGI)Committee chair and member roles
PACS Group (PACS)Post-acute healthcareLowCommittee chair and member roles
QuidelOrtho (QDEL)DiagnosticsLowDirector
Bailard Private RE FundReal estateLowDirector
ProtivitiConsultingLowAdvisory board

No related-party transactions involving Ms. Dilsaver are disclosed; related-party arrangements disclosed pertain to director Simon John Dyer’s joint ventures, with safeguards via the Related Party Transactions Policy and recusal .

Expertise & Qualifications

  • CPA; significant accounting, auditing, and financial skills; former CFO and asset management executive .
  • Board and governance experience across multiple public companies and sectors .
  • Audit Committee leadership and financial expert qualification via Audit Committee designation .

Equity Ownership

MetricValueNotes
Beneficial Ownership (Shares)151,580As of March 18, 2025
Ownership % of Class<1%“Represents ownership of less than 1% of class”
Options exercisable within 60 daysNo options or rights scheduled within 60 days
Anti-Hedging/PledgingProhibitedCompany-wide policy prohibiting hedging and pledging
Director Stock Ownership Guideline5x annual base feeDirectors must meet within five years; retention of 50% of net after-tax shares until compliant
Guideline Compliance (2024)In complianceAll executives and Directors maintained compliance in 2024

Governance Assessment

  • Positives: Independent director; Audit Chair with audit committee financial expert designation; strong board engagement (7 meetings; >75% attendance); anti-hedging/pledging policy; robust stock ownership guidelines with compliance; no related-party exposures disclosed for Ms. Dilsaver; director compensation mix balanced between cash retainer and equity RSUs; independent compensation consultant engaged for executive and director programs; strong investor support on say-on-pay (98% approval in 2024) .
  • Watch items: Multiple outside public company commitments warrant ongoing monitoring of time/attention, though no attendance shortfalls are disclosed; no overlapping ties with SGI’s key counterparties disclosed in proxy .
  • Governance structure: Related Party Transactions Policy administered by Nominating & Corporate Governance Committee; executive sessions led by Lead Director; committee self-evaluations conducted annually; Audit Committee oversight extends to cybersecurity, ESG disclosure controls, and legal/compliance .

RED FLAGS: None disclosed specific to Ms. Dilsaver. Anti-hedging/pledging policy reduces alignment risk; no Section 16(a) filing delinquencies reported for 2024 .